ArticlePublished 14 Mar 2024
Efficacy of Budesonide and Formoterol Inhalation Aerosol in Conjunction with Doxofylline in Chronic Obstructive Pulmonary Disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
To observe the clinical efficacy of budesonide/formoterol inhalation aerosol in conjunction with doxofylline in treating individuals with stable chronic obstructive pulmonary disease. Our study enrolled a total of 90 patients with stable chronic obstructive pulmonary disease, who were admitted to our hospital from September 2019 to June 2021. These participants were allocated randomly into two groups; the control group and the observation group, comprising 45 patients in each group. Doxofylline was administered to the control group, while the observation group received additional treatment of budesonide/formoterol inhalation aerosol alongside doxofylline. The duration of treatment for both groups was set at 6 mo. The clinical efficacy was determined by evaluating the improvement of clinical symptoms, along with the assessment of pulmonary function, and the measurement of serum levels of interleukin-8, transforming growth factor-beta 1, and tumor necrosis factor-alpha. With a total effective rate of 99.33 %, the observation group outperformed the control group, which achieved a rate of 73.33 %. The baseline measurements of pulmonary function indicators, as well as interleukin-8, transforming growth factor-beta 1, and tumor necrosis factor-alpha levels, showed no remarkable distinctions between the two groups. However, post-treatment evaluations revealed noteworthy improvements in the observation group's forced expiratory volume in the first second/forced vital capacity values compared to their respective pre-treatment levels. These improvements were notably higher than those observed in the control group (p 0.05). Budesonide/formoterol inhalation aerosol in conjunction with doxofylline in treating individuals with stable chronic obstructive pulmonary disease significantly improves clinical symptoms, enhances pulmonary function, exhibits good anti-inflammatory effects, and has a good safety profile.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Yanling Jiang”
- BylineArticles whose byline prints “Qingming Meng”
- BylineArticles whose byline prints “Junjie Chen”
- BylineArticles whose byline prints “Shuo Chen”